{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.070","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"45.1","value":"8.1"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"49.6","value":"8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Time to myeloma response is defined as the time from randomization to the time the response criteria for complete response (CR) or partial response (PR) are first met.\n\nResponse was assessed by the Independent Response Adjudication Committee (IRAC) using European Group for Blood and Bone Marrow Transplant (EBMT) criteria as described previously.\n\nData collection is ongoing and future data results will be included as available.","dispersionType":"Full Range","groups":[{"description":"Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (either 40mg or 20 mg) on days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"Phase 2: Pomalidomide + Dexamethasone"},{"description":"4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone at the starting dose in addition to their current dose of pomalidomide or to discontinue treatment.","id":"OG001","title":"Phase 2: Pomalidomide"}],"paramType":"MEDIAN","populationDescription":"Responders (participants achieving CR or PR) from ITT population.\n\nData collection is ongoing and future data results will be included as available.","reportingStatus":"POSTED","timeFrame":"up to 70 weeks","title":"Phase 2: Time to Response as of the 01 April 2011 Cut-off","type":"SECONDARY","unitOfMeasure":"weeks"}